Chemotherapy with trifluridine/tipiracil prolongs progression-free survival time and improves quality of life. A case report of 59-year-old woman with metastatic rectal cancer Case report

Main Article Content

Beata Kania-Zembaczyńska

Abstract

The paper presents a clinical case of a patient with a long-term response to IV line chemotherapy with trifluridine/tipiracil. The treatment allowed to maintain a good quality of life with acceptable side effects

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Kania-Zembaczyńska B. Chemotherapy with trifluridine/tipiracil prolongs progression-free survival time and improves quality of life. A case report of 59-year-old woman with metastatic rectal cancer. OncoReview [Internet]. 2020Mar.31 [cited 2024Mar.29];10(1(37):18-2. Available from: https://www.journalsmededu.pl/index.php/OncoReview/article/view/1078
Section
CARDIO-ONCOLOGY

References

1. European Medicines Agency. European public assessment report (EPAR) for Lonsurf. 2016. http://www.ema.europa.eu.
2. Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treatment Rev. 2015; 41: 777-83.
3. Mayer R, Van Cutsem E, Falcone A et al.; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372: 1909-19.
4. Funaioli C, Longobardi C, Martoni AA. The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials. J Chemother. 2008; 20: 14-27.
5. Van Cutsem E, Falcone A, Garcia-Carbonero R et al. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open. 2017; 2(5): e000261.